Logo

Ah, the Promise

Jun 24, 2009

GlaxoSmithKline's CEO Andrew Witty says that overhauling the company's drug discovery operation was a "major upheaval" but is now showing results. According to Reuters, Witty also says that in the last 15 years, the drug industry floundered by basing the discovery process on combinatorial chemistry, genomics, and proteomics. "These were all supposed to transform productivity yet none of them did. It turns out, in my view, that research is much more of an art than a science," Witty says.

Breaking News
The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Charged with Sanction Violations

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.